1 |
MAPK14
| [30] Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
2 |
MAPK14
| [30] Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
3 |
IL1A
| [8] Osteoclast differentiation Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
4 |
IL1A
| [8] Osteoclast differentiation Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Rheumatoid arthritis | D06635
D06635
|
Rilonacept
| [4] 51 51, 106, 107, 266 |
5 |
IL1A
| [8] Osteoclast differentiation Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Rheumatoid arthritis | D11253
D11253
|
Bermekimab
| [1] 51 51 |
6 |
IL1B
| [15] Osteoclast differentiation Osteoclast differentiation, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
7 |
IL1B
| [15] Osteoclast differentiation Osteoclast differentiation, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis | D06635
D06635
|
Rilonacept
| [4] 51 51, 106, 107, 266 |
8 |
IL1B
| [15] Osteoclast differentiation Osteoclast differentiation, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis | D09315
D09315
|
Canakinumab
| [10] 46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 |
9 |
IL1B
| [15] Osteoclast differentiation Osteoclast differentiation, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis | D09911
D09911
|
Gevokizumab
| [4] 41 41, 50, 56, 269 |
10 |
IL6
| [16] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
11 |
IL6
| [16] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D08976
D08976
|
Pomalidomide
| [6] 28 28, 34, 51, 85, 227, 331 |
12 |
IL6
| [16] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D09669
D09669
|
Siltuximab
| [2] 28 28, 331 |
13 |
IL6
| [16] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D10080
D10080
|
Sirukumab
| [2] 41 41, 46 |
14 |
IL6R
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer | D02596
D02596
|
Tocilizumab
| [21] 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
15 |
IL6R
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer | D10161
D10161
|
Sarilumab
| [5] 41 41, 46, 84, 107, 271 |
16 |
IL6R
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer | D11079
D11079
|
Satralizumab
| [2] 11 11, 13 |
17 |
INSR
| [8] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease | D00085
D00085
|
Insulin human
| [2] 96 96, 156 |
18 |
INSR
| [8] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease | D03230
D03230
|
Insulin human
| [2] 96 96, 156 |
19 |
INSR
| [8] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease | D03250
D03250
|
Insulin glargine
| [1] 299 299 |
20 |
INSR
| [8] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease | D04539
D04539
|
Insulin detemir
| [1] 299 299 |
21 |
LEPR
| [1] Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease | D05014
D05014
|
Metreleptin
| [1] 265 265 |
22 |
MAP3K5
| [10] Platinum drug resistance Platinum drug resistance, Sphingolipid signaling pathway, Protein processing in endoplasmic reticulum, Tight junction, TNF signaling pathway, Thermogenesis, Non-alcoholic fatty liver disease, Parkinson disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases | D10988
D10988
|
Selonsertib
| [1] 86 86 |
23 |
NFKB1
| [28] Ras signaling pathway Ras signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D01146
D01146
|
Iguratimod
| [4] 46 46, 51, 53, 271 |
24 |
PIK3CA
| [36] Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| [2] 53 53, 65 |
25 |
PIK3CB
| [36] Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| [2] 53 53, 65 |
26 |
PIK3CD
| [36] Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| [2] 53 53, 65 |
27 |
PIK3CD
| [36] Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11437
D11437
|
Parsaclisib
| [3] 35 35, 53, 61 |
28 |
PPARA
| [2] PPAR signaling pathway PPAR signaling pathway, Non-alcoholic fatty liver disease | D00565
D00565
|
Fenofibrate
| [5] 8 8, 79, 93, 94, 265 |
29 |
PPARA
| [2] PPAR signaling pathway PPAR signaling pathway, Non-alcoholic fatty liver disease | D01366
D01366
|
Bezafibrate
| [7] 20 20, 93, 94, 160, 296, 316, 324 |
30 |
PPARA
| [2] PPAR signaling pathway PPAR signaling pathway, Non-alcoholic fatty liver disease | D10711
D10711
|
Pemafibrate
| [1] 93 93 |
31 |
PPARA
| [2] PPAR signaling pathway PPAR signaling pathway, Non-alcoholic fatty liver disease | D11208
D11208
|
Elafibranor
| [1] 93 93 |
32 |
PPARG
| [7] PPAR signaling pathway PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer | D00596
D00596
|
Rosiglitazone
| [5] 46 46, 75, 97, 222, 265 |
33 |
PPARG
| [7] PPAR signaling pathway PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer | D00945
D00945
|
Pioglitazone
| [17] 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
34 |
PPARG
| [7] PPAR signaling pathway PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer | D08378
D08378
|
Pioglitazone
| [17] 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
35 |
PPARG
| [7] PPAR signaling pathway PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer | D08491
D08491
|
Rosiglitazone
| [5] 46 46, 75, 97, 222, 265 |
36 |
PPARG
| [7] PPAR signaling pathway PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer | D11256
D11256
|
Seladelpar
| [2] 93 93, 94 |
37 |
PPARG
| [7] PPAR signaling pathway PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer | D11603
D11603
|
Leriglitazone
| [1] 20 20 |
38 |
PRKAA1
| [5] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease | D00944
D00944
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
39 |
PRKAA1
| [5] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease | D04966
D04966
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
40 |
PRKAA2
| [5] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease | D00944
D00944
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
41 |
PRKAA2
| [5] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease | D04966
D04966
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
42 |
MAPK11
| [30] Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
43 |
MAPK11
| [30] Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
44 |
MAPK13
| [30] Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
45 |
MAPK13
| [30] Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
46 |
RELA
| [28] Ras signaling pathway Ras signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D12181
D12181
|
Edasalonexent
| [1] 113 113 |
47 |
RXRA
| [11] PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer | D02754
D02754
|
Acitretin
| [1] 37 37 |
48 |
RXRA
| [11] PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer | D02815
D02815
|
Alitretinoin
| [1] 49 49 |
49 |
RXRA
| [11] PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer | D03106
D03106
|
Bexarotene
| [2] 13 13, 75 |
50 |
MAPK12
| [30] Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
51 |
MAPK12
| [30] Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
52 |
TGFB1
| [12] TGF-beta signaling pathway TGF-beta signaling pathway, Osteoclast differentiation, Th17 cell differentiation, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Toxoplasmosis, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Rheumatoid arthritis | D09620
D09620
|
Fresolimumab
| [4] 51 51, 85, 222, 274 |
53 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D00742
D00742
|
Etanercept
| [17] 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298 |
54 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D00754
D00754
|
Thalidomide
| [20] 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
55 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
56 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D02597
D02597
|
Adalimumab
| [18] 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 |
57 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D02598
D02598
|
Infliximab
| [27] 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
58 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D03441
D03441
|
Certolizumab pegol
| [8] 37 37, 46, 49, 96, 97, 107, 226, 271 |
59 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D04358
D04358
|
Golimumab
| [8] 46 46, 56, 84, 96, 97, 107, 270, 271 |
60 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D04687
D04687
|
Lenalidomide
| [8] 16 16, 26, 28, 34, 49, 284, 300, 331 |
61 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D05393
D05393
|
Pegsunercept
| [1] 46 46 |
62 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D08976
D08976
|
Pomalidomide
| [6] 28 28, 34, 51, 85, 227, 331 |
63 |
TNF
| [23] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D09944
D09944
|
Ozoralizumab
| [1] 46 46 |